Your browser doesn't support javascript.
Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF-κB: A Systematic Review.
Peddapalli, Apparao; Gehani, Manish; Kalle, Arunasree M; Peddapalli, Siva R; Peter, Angela E; Sharad, Shashwat.
  • Peddapalli A; Department of Microbiology, King George Hospital, Visakhapatnam 531011, Andhra Pradesh, India.
  • Gehani M; Department of Biological Sciences, Birla Institute of Technology and Science, Pilani-Hyderabad Campus, Hyderabad 500078, Telangana, India.
  • Kalle AM; Department of Animal Biology, School of Life Sciences, University of Hyderabad, Hyderabad 500046, Telangana, India.
  • Peddapalli SR; Department of Biological Sciences-Biotechnology, Florida Institute of Technology, Melbourne, FL 32901, USA.
  • Peter AE; Department of Biotechnology, College of Science & Technology, Andhra University, Visakhapatnam 530003, Andhra Pradesh, India.
  • Sharad S; Center for Prostate Disease Research, John P. Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD 20817, USA.
Viruses ; 13(3)2021 02 27.
Article in English | MEDLINE | ID: covidwho-1190473
ABSTRACT
The immunological findings from autopsies, biopsies, and various studies in COVID-19 patients show that the major cause of morbidity and mortality in COVID-19 is excess immune response resulting in hyper-inflammation. With the objective to review various mechanisms of excess immune response in adult COVID-19 patients, Pubmed was searched for free full articles not related to therapeutics or co-morbid sub-groups, published in English until 27.10.2020, irrespective of type of article, country, or region. Joanna Briggs Institute's design-specific checklists were used to assess the risk of bias. Out of 122 records screened for eligibility, 42 articles were included in the final review. The review found that eventually, most mechanisms result in cytokine excess and up-regulation of Nuclear Factor-κB (NF-κB) signaling as a common pathway of excess immune response. Molecules blocking NF-κB or targeting downstream effectors like Tumour Necrosis Factor α (TNFα) are either undergoing clinical trials or lack specificity and cause unwanted side effects. Neutralization of upstream histamine by histamine-conjugated normal human immunoglobulin has been demonstrated to inhibit the nuclear translocation of NF-κB, thereby preventing the release of pro-inflammatory cytokines Interleukin (IL) 1ß, TNF-α, and IL-6 and IL-10 in a safer manner. The authors recommend repositioning it in COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulins / Histamine / NF-kappa B / Cytokine Release Syndrome / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: V13030378

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulins / Histamine / NF-kappa B / Cytokine Release Syndrome / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: V13030378